CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into...

CRISPR Therapeutics在ASH 2024上重點介紹CTX112數據，展示了在復發/難治的CD19陽性b細胞惡性腫瘤中的潛在臨床益處；獲得FDA RMAt認證，適用於濾泡性和邊緣區淋巴瘤，並正在擴展至I期試驗...

Benzinga · 12/10 01:03

CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into Autoimmune Indications And Broader Updates Expected In Mid-2025

CRISPR Therapeutics在2024年ASH大會上重點介紹了CTX112的數據，展示了在復發/難治性CD19陽性B細胞惡性腫瘤中的潛在臨床益處；獲得FDA的RMAt認證，適用於濾泡性淋巴瘤和邊緣區淋巴瘤，一級臨床試驗擴大到自身免疫性疾病，預計將在2025年中期發佈更廣泛的更新。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。